Compare Mesoblast Limited (MESO) vs NICE Ltd (NICE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs NICE Ltd — how do they compare? Mesoblast Limited trades at $16.68 (market cap $2.16B), while NICE Ltd trades at $101.98 (market cap $5.99B). The key difference: NICE Ltd is far larger — about 2.8× Mesoblast Limited's market cap, and Mesoblast Limited is trading nearer its 52-week high, NICE Ltd nearer its low. Which is the better fit depends on your goals.
| MESO | NICE | |
|---|---|---|
Market Cap | $2.16B | $5.99B |
Sector | Technology | Technology |
52-Week High | $20.96 | $153.44 |
52-Week Low | $12.88 | $83.15 |
Enterprise Value | $2.17B | $5.72B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.
Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.
NICE stock trades at $101.85, up 4.88% today, showing strong momentum after exceeding Q2 2026 earnings expectations with $2.70 EPS versus $2.63 expected. The company maintains solid fundamentals with 65.12% gross margins and 13.86% net income margin, while technical indicators show bullish momentum with key resistance at $103. Recent partnerships with RingCentral and ESG initiatives highlight strategic growth positioning.
The outlook remains positive with analyst consensus target of $115 suggesting 13% upside potential. Key risks include competitive pressures in customer engagement software and potential margin compression as revenue growth outpaces profit growth. Institutional ownership trends show mixed activity with some firms increasing positions while others trim holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →
